{
    "clinical_study": {
        "@rank": "151215", 
        "arm_group": {
            "arm_group_label": "Intrabone transplantation", 
            "arm_group_type": "Experimental", 
            "description": "Direct intrabone transplantation procedure of peripheral blood haematopoietic stem cells form HLA-matched sibling donors in patients with myeloid and lymphoid malignancies."
        }, 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate efficacy and safety of direct intrabone\n      transplantation procedure of peripheral blood haematopoietic stem cells form HLA-matched\n      sibling donors in patients with myeloid and lymphoid malignancies."
        }, 
        "brief_title": "Intrabone Transplantation of Allogenic Peripheral Blood Stem Cells in Patients With Myeloid and Lymphoid Malignancies.", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Leukemia", 
            "Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Lymphoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "Allogenic haematopoietic stem cell transplantation is an established treatment option for\n      haematologic malignancies, especially leukaemias and lymphomas, providing curative\n      potential. The optimal donor is HLA-matched sibling and G-CSF stimulated peripheral blood is\n      nowadays the most common source of stem cells. Routinely used route of stem cell\n      transplantation is intravenous infusion via central venous catheter. Based on the animal\n      studies, only 10-15% of intravenously transplanted stem cells migrate to haematopoietic\n      sites while the rest is lost in other organs. Results of studies of direct intrabone\n      allogenic cord-blood cells transplantation in humans confirm that this route of\n      transplantation is associated with less probability of graft failure and moreover may reduce\n      risk of graft-versus-host disease and malignancy relapse. For those purposes in the current\n      study we investigate intrabone route of allogenic peripheral blood stem cell\n      transplantation. Our intention is to achieve fast engraftment and minimize risk of relapse\n      and graft graft-versus-host disease."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18-55 years\n\n          -  Diagnosis of leukaemia or lymphoma\n\n          -  Indication for allogenic stem cell transplantation according to European  Group for\n             Blood and Marrow Transplantation guidelines\n\n          -  HLA-matched sibling donor qualified for peripheral blood stem cell donation\n\n          -  Performance status WHO 0-1\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Organ dysfunction: elevated ALT, AST, bilirubin, AF; creatinine >1.5 upper normal\n             limit; LVEF <45%\n\n          -  Active infection\n\n          -  Unstable diabetes\n\n          -  Psychiatric diseases\n\n          -  Obesity or anatomical obstacle for direct intrabone transplantation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01728389", 
            "org_study_id": "IBT-COI-01"
        }, 
        "intervention": {
            "arm_group_label": "Intrabone transplantation", 
            "description": "Direct intrabone transplantation procedure of peripheral blood haematopoietic stem cells form HLA-matched sibling donors in patients with myeloid and lymphoid malignancies.", 
            "intervention_name": "Intrabone transplantation", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "allogenic stem cell transplantation", 
            "peripheral blood stem cells", 
            "intrabone", 
            "intra-bone", 
            "leukemia", 
            "lymphoma"
        ], 
        "lastchanged_date": "July 23, 2013", 
        "location": {
            "contact": {
                "email": "ots@io.gliwice.pl", 
                "last_name": "Sebastian Giebel, Assoc. prof.", 
                "phone": "+48322788523"
            }, 
            "facility": {
                "address": {
                    "city": "Gliwice", 
                    "country": "Poland", 
                    "zip": "44-101"
                }, 
                "name": "MSC Memorial CAncer Center and Institute of Oncology"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Poland"
        }, 
        "number_of_arms": "1", 
        "official_title": "Efficacy and Safety of Direct Intrabone Transplantation of Peripheral Blood Haematopoietic Stem Cells Form HLA-matched Sibling Donors in Patients With Myeloid and Lymphoid Malignancies.", 
        "other_outcome": [
            {
                "measure": "Relapse incidence", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Disease-free survival", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Graft-versus-host disease incidence", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "overall_contact": {
            "email": "tomcmed@poczta.onet.pl", 
            "last_name": "Tomasz Czerw, MD", 
            "phone": "+48 32 2788523"
        }, 
        "overall_contact_backup": {
            "email": "sgiebel@io.gliwice.pl", 
            "last_name": "Sebastian Giebel, MD", 
            "phone": "+48 32 2788523"
        }, 
        "overall_official": {
            "affiliation": "Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland", 
            "last_name": "Tomasz Czerw, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Poland: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Neutrophil engraftment (ANC > 0,5 G/l)", 
            "safety_issue": "No", 
            "time_frame": "28 days"
        }, 
        "reference": [
            {
                "PMID": "18693069", 
                "citation": "Frassoni F, Gualandi F, Podest\u00e0 M, Raiola AM, Ibatici A, Piaggio G, Sessarego M, Sessarego N, Gobbi M, Sacchi N, Labopin M, Bacigalupo A. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol. 2008 Sep;9(9):831-9. Epub 2008 Aug 8."
            }, 
            {
                "PMID": "21867667", 
                "citation": "Okada M, Yoshihara S, Taniguchi K, Kaida K, Ikegame K, Kato R, Tamaki H, Inoue T, Soma T, Kai S, Kato S, Ogawa H. Intrabone marrow transplantation of unwashed cord blood using reduced-intensity conditioning treatment: a phase I study. Biol Blood Marrow Transplant. 2012 Apr;18(4):633-9. doi: 10.1016/j.bbmt.2011.08.010. Epub 2011 Aug 23."
            }, 
            {
                "PMID": "20550953", 
                "citation": "Massollo M, Podest\u00e0 M, Marini C, Morbelli S, Cassanelli C, Pinto V, Ubezio G, Curti G, Uccelli A, Frassoni F, Sambuceti G. Contact with the bone marrow microenvironment readdresses the fate of transplanted hematopoietic stem cells. Exp Hematol. 2010 Oct;38(10):968-77. doi: 10.1016/j.exphem.2010.06.003. Epub 2010 Jun 13."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01728389"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Lineage chimerism of peripheral blood T-cell lymphocytes", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Platelet engraftment (Plt > 20 G/l)", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "measure": "Adverse reactions related with intrabone transplantation procedure", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }
        ], 
        "source": "Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}